Changes in the Gustave Roussy Immune Score as a Powerful Prognostic Marker of the Therapeutic Sensitivity of Nivolumab in Advanced Gastric Cancer: A Multicenter, Retrospective Study

[1]  H. Saeki,et al.  Clinical features as potential prognostic factors in patients treated with nivolumab for highly pretreated metastatic gastric cancer: a multicenter retrospective study , 2022, BMC cancer.

[2]  M. Noguchi,et al.  [Neutrophil-to-Lymphocyte Ratio(NLR)as a Predictive Indicator of the Response to Nivolumab in Patients with Oral Squamous Cell Carcinoma]. , 2021, Gan to kagaku ryoho. Cancer & chemotherapy.

[3]  K. Shirabe,et al.  An Elevated Serum Lactate Dehydrogenase-to-albumin Ratio Is a Useful Poor Prognostic Predictor of Nivolumab in Patients With Gastric Cancer , 2021, Anticancer Research.

[4]  A. Dingemans,et al.  The Gustave Roussy Immune (GRIm)-Score Variation Is an Early-on-Treatment Biomarker of Outcome in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Treated with First-Line Pembrolizumab , 2021, Journal of clinical medicine.

[5]  S. Cho,et al.  Chromatin accessibility of circulating CD8+ T cells predicts treatment response to PD-1 blockade in patients with gastric cancer , 2021, Nature Communications.

[6]  U. Aday,et al.  Prognostic significance of pretreatment serum lactate dehydrogenase-to-albumin ratio in gastric cancer , 2020, Contemporary oncology.

[7]  M. Chang,et al.  Prognostic perspectives of PD-L1 combined with tumor-infiltrating lymphocytes, Epstein-Barr virus, and microsatellite instability in gastric carcinomas , 2020, Diagnostic Pathology.

[8]  Takaaki Masuda,et al.  Prognostic Significance of PD-1, PD-L1 and CD8 Gene Expression Levels in Gastric Cancer , 2020, Oncology.

[9]  L. Mezquita,et al.  The Lung Immune Prognostic Index (LIPI) stratifies prognostic groups in advanced non-small cell lung cancer (NSCLC) patients , 2020, Translational lung cancer research.

[10]  E. Vasile,et al.  Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study , 2020, Advances in Therapy.

[11]  D. Takahari,et al.  Changes in the neutrophil-to-lymphocyte ratio during nivolumab monotherapy are associated with gastric cancer survival , 2020, Cancer Chemotherapy and Pharmacology.

[12]  Liang Wang,et al.  Gustave Roussy Immune Score (GRIm-Score) is a prognostic marker in patients with resectable esophageal squamous cell carcinoma , 2020, Journal of Cancer.

[13]  M. Takumida,et al.  Baseline neutrophil-to-lymphocyte ratio (NLR) is associated with clinical outcome in recurrent or metastatic head and neck cancer patients treated with nivolumab , 2019, Acta oto-laryngologica.

[14]  Y. Jiang,et al.  Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432 , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  S. Minami,et al.  Gustave Roussy Immune Score and Royal Marsden Hospital Prognostic Score Are Biomarkers of Immune-Checkpoint Inhibitor for Non-Small Cell Lung Cancer , 2019, World journal of oncology.

[16]  G. Madonna,et al.  Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab , 2018, Journal of Immunotherapy for Cancer.

[17]  T. Yoshikawa,et al.  Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial , 2017, The Lancet.

[18]  J. Soria,et al.  Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score). , 2017, European journal of cancer.

[19]  Hidekazu Suzuki,et al.  Predictive Factors for Poor Progression-free Survival in Patients with Non-small Cell Lung Cancer Treated with Nivolumab. , 2017, Anticancer research.

[20]  Limei Qu,et al.  PD-1 and PD-L1 co-expression predicts favorable prognosis in gastric cancer , 2017, Oncotarget.

[21]  Y. Bang,et al.  Prognostic implication of antitumor immunity measured by the neutrophil–lymphocyte ratio and serum cytokines and angiogenic factors in gastric cancer , 2017, Gastric Cancer.

[22]  A. Jemal,et al.  Global cancer statistics, 2012 , 2015, CA: a cancer journal for clinicians.

[23]  K. Yamashita,et al.  Trend in gastric cancer: 35 years of surgical experience in Japan. , 2011, World journal of gastroenterology.

[24]  E. Bourdon,et al.  The antioxidant properties of serum albumin , 2008, FEBS letters.

[25]  Chien-Jen Chen,et al.  Elevated plasma osteopontin associated with gastric cancer development, invasion and survival , 2006, Gut.

[26]  L. Paz-Ares,et al.  Blood Predictive Biomarkers for Patients With Non-small-cell Lung Cancer Associated With Clinical Response to Nivolumab. , 2019, Clinical lung cancer.

[27]  R. Herbst,et al.  Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer. , 2016, JAMA oncology.

[28]  J. Coward,et al.  Interleukin-6: an angiogenic target in solid tumours. , 2014, Critical reviews in oncology/hematology.

[29]  Y. Maehara,et al.  Neutrophil-lymphocyte ratio reflects hepatocellular carcinoma recurrence after liver transplantation via inflammatory microenvironment. , 2013, Journal of hepatology.

[30]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[31]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.